The National Institute for Health and Care Excellence (NICE) has recently recommended the exploration of virtual wards in healthcare. Virtual care is not a new concept. Recent health crises, like the COVID-19 pandemic, have propelled it into the spotlight. Virtual care, including telehealth and remote patient monitoring, has shown great promise in improving access to care, especially for those in remote or underserved areas. For example, early warning scores, such as NEWS2 and CRB65, are transforming the way we assess patients with suspected Acute Respiratory Infections (ARIs). These scores offer a promising avenue for clinical decision-making, especially in remote settings like call centres or primary care. They can be instrumental in determining care pathways, such as whether to send patients home, to ARI virtual wards, or to same day emergency care.
Remote contact with National Health Service (NHS) services is gaining momentum. The guideline committee has made recommendations based on their expertise and experience, despite the fact that there is a lack of evidence on the use of remote assessments for those who have a suspicion that they have ARI. They are of the opinion that remote evaluations can be a beneficial tool for identifying persons who do not have major illnesses. However, they believe that an in-person assessment is essential for people who do have severe diseases.
The committee has also emphasised the significance of accessibility. Recognising that not everyone has equal access to or the capacity to use digital technology. However, they have emphasised the value of accessibility nonetheless. As a result, they have suggested that alternatives should be provided whenever they are required, and that the NHS has a responsibility to give reasonable adjustments to patients who have requirements in this regard.
As a result of the committee’s recommendations, antimicrobial stewardship is expected to be improved. This will lead to the beginning of a new era in healthcare. This will be accomplished by reducing the amount of antimicrobials that are prescribed without an in-person assessment.
💊 Could MFN Pricing Undermine Biosimilars?
MFN drug pricing aims to cut costs—but its indirect pressure on biosimilars may reduce competition (create a void) and raise long-term prices.
Explore the risks and what stakeholders can do to protect market sustainability.
#SyenzaNews #Biosimilars #DrugPricing #HealthPolicy #Pharma #MarketAccess
🔍 Are you prepared for the upcoming EU AI Act in healthcare?
As the first comprehensive AI regulation globally rolls out, healthcare organizations must move beyond mere compliance. The urgency lies in embedding ethical, trusted, and sustainable AI practices into every facet of healthcare AI. Early adoption of ethical assessments and collaboration is essential to navigate the complex regulatory landscape before the August 2026 deadline.
Learn about proactive compliance strategies that not only meet regulatory standards but also enhance patient trust and system efficacy!
#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation
💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?
A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.
Join the conversation on enhancing vaccination strategies for better health outcomes!
#SyenzaNews #Healthcare #HealthEconomics
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
